

The FDA has cleared Optovue's optical coherence tomography angiography system, the [AngioVue System](#), for commercial sale. AngioVue provides a new, non-invasive way to visualize abnormal blood vessels in the retina to help physicians determine an appropriate course of treatment.



In less than three seconds, the AngioVue System acquires a single image that complements the current angiography imaging standard, fluorescein angiography (FA), but with a number of advantages. Unlike FA, the AngioVue System does not require the use of dye injections, which can often obscure the target anatomy and can lead to side effects and other complications associated with dye-based, invasive procedures.